Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Substance Profile
N,N-Dimethyltryptamine (DMT) is a naturally occurring tryptamine found in numerous plants and animals, considered one of the most potent short-acting psychedelics. When smoked, it produces an intense but brief psychedelic experience within seconds, lasting 15-30 minutes. In the traditional ayahuasca preparation, DMT is combined with an MAO inhibitor (typically Banisteriopsis caapi), enabling oral bioavailability and extending the duration to 4-6 hours. Research is investigating DMT and ayahuasca for depression, substance use disorders, and post-traumatic stress disorder.
Rapid-onset serotonin 2A activation producing intense visual phenomena
Modulates calcium signaling and cellular stress response
Harmine/harmaline inhibit MAO-A enabling oral DMT bioavailability
Reported subjective effects based on clinical and community data
Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.
Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.
Streamlining Eligibility Assessment for Alzheimer's Disease-Modifying Therapies: Prediction of MMSE Scores Using the Digital Clock and Recall.
Beyond the toad's kiss: Mapping acute 5-MeO-DMT effects on brain connectivity across sex and dose using awake rat neuroimaging.
Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
LGBTQ+ Ayahuasca Retreat Experience is Associated with Benefits to Mental Health, Quality of Life, and Spiritual Well-Being: A Prospective, Naturalistic Study.
Determinants of change in disease-modifying drugs in patients with multiple sclerosis: A registry-based study.
Analysis of herpes zoster cases in multiple sclerosis patients treated with disease-modifying drugs: insights from the EudraVigilance database.
The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naïve patients with multiple sclerosis.
Effects of disease modifying therapy on cognitive proficiency in pediatric-onset multiple sclerosis (POMS).
Association of cytokine levels with treatment duration and patient family history in Egyptian multiple sclerosis patients.
Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice.
Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.
Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Filipino Patients With Multiple Sclerosis: A Single-Center Retrospective Case Series.
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies.
5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation.
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.
Safety of breastfeeding under monoclonal antibodies in the offspring of mothers with multiple sclerosis or neuromyelitis optica spectrum disorder.
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.
The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health.
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.
Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.
Serotonergic psychedelics for depression: A comprehensive overview.
Clinical pharmacology.
Human neuroimaging: fMRI.
Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.
Psychedelics, entactogens and psychoplastogens for depression and related disorders.
Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.
The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.
Ayahuasca-inspired DMT/HAR formulation reduces brain differentiation between self and other faces.
Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.
Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression.
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.
Ayahuasca: pharmacology, safety, and therapeutic effects.
Is there a place for psychedelics in sports practice?
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.
Psychedelics in neuroinflammation: Mechanisms and therapeutic potential.
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.
Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.
The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.